Cancer vaccine prevents deadly melanoma from returning or spreading in landmark trial

A Phase 3 endpoint isn't a cure, but the headlines already reached for the word 'landmark.'

Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma patients after surgery.